Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CS First Boston Upgrades Praecis Pharmaceutical


CS First Boston upgraded Praecis Pharmaceutical (PRCS ) to strong buy from buy.

On Tuesday, Amgen and Praecis received a letter from FDA indicating that the information presented for the companies' jointly created drug, Plenaxis, was inadequate. Analyst Meirov Chevav says the sharp decline in price following the FDA's response on Abarelix (Plenaxis) creates a buying opportunity. He thinks at the current stock price, no value is being paid for Abarelix in any indication. If Abarelix is approved over the next six to twelve months as he expects, Praecis' stock price could easily double or triple from here. Chevav widened his $1.40 2001 loss estimate to a $1.51 loss; and narrowed the $1.30 2002 loss to $1.25 loss and the $1.15 2003 loss to a $1.05 loss. He has a $50 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus